Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Shares of Summit Therapeutics (NASDAQ:SMMT) ended five straight sessions of gains on Friday as the stock lost ~35%, ...

If generative AI could contribute in the slightest to such discoveries—as has been promised since the start of the AI ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Summit Therapeutics stock tumbled 37% on Friday afternoon after the U.S. Food and Drug Administration (FDA) approved its ...

Waksal, who is not a medical doctor, imported the veterinary drug along with other “unapproved ingredients” from Colombia.